Nature Reviews Clinical Oncology

Article	Citations
Tasadenoturev active in DIPG	1000
A new standard of care for advanced-stage urothelial carcinoma	1000
From little subclones grow mighty oaks	783
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	771
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	718
Ecological management of the microbiota in patients with cancer	713
Novel ICI–TKI combination improves HCC outcomes	709
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	609
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	606
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	576
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	551
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	507
Hodgkin lymphoma: great progress with room for improvement	486
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	460
Current understanding and management of CAR T cell-associated toxicities	427
Gut microbiota in colorectal cancer development and therapy	422
Contrasting results with second-line CAR T cells in large B cell lymphoma	416
Sacituzumab tirumotecan improves OS in mTNBC	391
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	384
Ponatinib superior to imatinib in Ph+ ALL	382
Mortality is similar with active monitoring	378
From ESMO 2022	376
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	365
Belzutifan as a new option in pheochromocytomas and paragangliomas	338
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	288

Understanding and overcoming multidrug resistance in cancer	285
Harnessing cytokines and chemokines for cancer therapy	283
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	283
Humanized mouse models for immuno-oncology research	279
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	277
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	277
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	275
Survival benefit with second-line combination in endometrial cancer	272
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	270
Craniospinal irradiation improves leptomeningeal metastasis control	269
Improving outcomes in patients with oesophageal cancer	262
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	261
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	261
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	246
Biomarkers for immunotherapy of hepatocellular carcinoma	239
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	239
Harnessing big data to characterize immune-related adverse events	238
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	204
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	195
Spatial landscapes of cancers: insights and opportunities	195
New CAPSTONE of SCLC therapy?	193
SHINE a light: frontline ibrutinib for MCL	191
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	185
Women with clinically node negative breast cancer can safely avoid axillary surgery	172
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	171
From ESMO 2023: advances in lung cancer	170
Prospective comparisons support the use of navigational bronchoscopy	155
DREAMseq of therapy for BRAF-mutant melanoma	155
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	144
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	143
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	141
Mitigating acute chemotherapy-associated adverse events in patients with cancer	137
Targeting chromosomal instability in patients with cancer	135
Circulating tumour DNA — looking beyond the blood	134
Long-term outcomes following CAR T cell therapy: what we know so far	125
Response to neoadjuvant endocrine therapy complements recurrence score	125
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	121
Multiomics STEP up in correlative analysis of response to CAR T cells	120
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	120
From the ESMO Congress 2023	119
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	118
Sentinel lymph node biopsy improves surgical management of cervical cancer	117
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	107
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	104
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	103
HAIC-FO improves outcomes in HCC	101
Newly approved cancer drugs in China — innovation and clinical benefit	100
Lung cancer in patients who have never smoked — an emerging disease	99
Clinical implications of T cell exhaustion for cancer immunotherapy	97

Claudin 18.2 as a novel therapeutic target	97
Enhancing immunotherapy with tumour-responsive nanomaterials	95
Combining CAR T cells effective in RRMM	95
Targeted biopsy reduces detection of clinically insignificant cancer	94
T-DXd effective as second-line therapy in G/GEJ cancers	93
Second-line tarlatamab improves OS in SCLC	90
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	89
Less-frequent surveillance is noninferior to annual mammography	86
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	86
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	81
Barriers in access to oncology drugs — a global crisis	79
Translating biological insights into improved management of endometrial cancer	78
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	75
Two decades of advances in clinical oncology — lessons learned and future directions	75
BrECADD raises the bar in classical Hodgkin lymphoma	74
HSCT prolongs remission of high-risk CTCLs	73
Nirogacestat effective in desmoid tumours	73
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	71
Thermal ablation is safer than resection of colorectal liver lesions	70
Cured but breathless: the growing burden of DIILD in cancer survivors	69
Promising OS with oncolytic virotherapy	68
GPRC5D-CAR T cells active in MM	66
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	66
Promise with co-administration of CAR T cells	65
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	65
Non-financial conflicts of interest	63
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	58
Efficacy of TILs confirmed	56
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	51
Exploiting bacteria for cancer immunotherapy	49
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	49
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	48
Neoadjuvant pembrolizumab improves outcomes	47
The current state of the art and future trends in RAS-targeted cancer therapies	47
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
KN046 shows tolerability and activity in TNBC	45
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	45
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	44
Problematic crossovers in cancer drug trials	42
LAG3 inhibition improves outcomes	40
Integrated MRI-guided radiotherapy — opportunities and challenges	39
The emerging roles of γδ T cells in cancer immunotherapy	38
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	38
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	35
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	35
National value-based pricing negotiation for oncology drugs — lessons from China	34
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	31
CAR T cells induce durable remission of neuroblastoma	27
GPRC5D as a novel immunotherapeutic target in multiple myeloma	27
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	26
Personalizing adjuvant therapy for patients with colorectal cancer	25
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	25
Epcoritamab is active in large B cell lymphomas	23
Laparoscopic TME is non-inferior	23
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	22
Menin–KMT2A interaction inhibitor shows promise	21
Laparoscopic hemihepatectomy is safe and effective	21
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	21
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	20
Adjuvant chemotherapy improves OS in UTUC	20
The microbiota in radiotherapy-induced cancer immunosurveillance	19
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC	19
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	19
The age of foundation models	18
Synthetic lethal strategies for the development of cancer therapeutics	17
HER2-targeted therapies beyond breast cancer — an update	17
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	16
Platinum-ineligible: atezolizumab preferable	16
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	15
Early promising results with the novel KRASG12C inhibitor divarasib	15
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	15
Pembrolizumab reduces recurrence risk in stage II melanoma	15
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	14
Precision oncology for KRASG12C-mutant colorectal cancer	14
Will I feel better? Raising the bar for quality of life in oncology	14
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	14
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations	14
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	13
The next generation of immunotherapies for lung cancers	13
Getting the right combination to break the epigenetic code	13

Cancer mRNA vaccines: clinical advances and future opportunities	12
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	12
Engaging results with glofitamab in DLBCL	12
Risk-adjusting away volume as a quality metric for surgical oncology: a perspective worth re-visiting	12
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	12
T-DXd is effective after T-DM1	12
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	12
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	11
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	11
Fertility support for patients with gynaecological cancers — a vital but neglected issue	11
Dabrafenib–trametinib moves to the first line in low-grade glioma	10
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	10
Thermal immuno-nanomedicine in cancer	10
A new first-line option for advanced-stage anal squamous cell carcinoma	9
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	9
New treatment strategies for advanced-stage gastrointestinal stromal tumours	8
HER2-directed therapy improves urothelial cancer outcomes	8
Is NETTER-2 a practice-changing trial?	8
Gut microbes as biomarkers of ICI response — sharpening the focus	8
Towards biomarker-driven therapies for urothelial carcinoma	8
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer	8
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	8
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	8
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	7
A new era for glioma therapy — targeting mutant IDH	7
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	7
Molecular tumour boards — current and future considerations for precision oncology	7
The molecular blueprint of targeted radionuclide therapy	7
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	7
Targeting cuproplasia and cuproptosis in cancer	6
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	6
Perioperative therapy effective in high-risk HCC	6
Criteria for the translation of radiomics into clinically useful tests	6
Dostarlimab effective in dMMR LARC	6
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	6
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	6
Synergy of EphB2 and PD-1 blockade	6
SUNLIGHT illuminates the activity of bevacizumab	6
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	6
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	6
Neoantigen vaccines at the crossroads: lessons from AMPLIFY-201	5
Prospective insights on the use of bTMB	5
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	5
Maintenance capecitabine is beneficial in NPC	5
Asciminib is safe and effective in patients with newly diagnosed CML	5
The SONIA trial shows the power and challenges of academic research	5
Combination neoadjuvant chemotherapy improves outcomes	5
Blinatumomab improves outcomes in infant ALL	5
Adjuvant S-1 extends OS in biliary tract cancers	5
Targeting the glioblastoma resection margin with locoregional nanotechnologies	5
The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma	5
AI accurately identifies targetable alterations in lung cancer histological images	5
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	5
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	5
Darolutamide combo is a sensible option for mHSPC	5
Circulating tumour cells for early detection of clinically relevant cancer	5
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	5
Transanal TME noninferior to the laparoscopic approach	5
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	5
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer	4
Envisioning trans-inclusive and trans-specific cancer care	4
Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours	4
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	4
Author Correction: Clinical relevance of tumour-associated macrophages	4
Towards equitable AI in oncology	4
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	4
Adjuvant nivolumab shows promise in MCC	4
Second-line axi-cel improves overall survival	4
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?	4
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	4
From WCC 2022	4
Leptomeningeal metastatic disease: new frontiers and future directions	4
Novel combination delivers prolonged OS	4
Early promising results with addition of an ICI and an anti-angiogenic to TACE	4
Pembrolizumab improves EFS in TNBC	4
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions	4
Rare molecular subtypes of lung cancer	4
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	4
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
Pharmacological reactivation of p53 in the era of precision anticancer medicine	3
Computational immunogenomic approaches to predict response to cancer immunotherapies	3
Overall survival as a primary end point in multiple myeloma trials	3
Abundant circulating lipids — a new opportunity for NSCLC detection?	3
Optimizing CAR T cell therapy for solid tumours: a clinical perspective	3
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?	3
CAR T cells show superiority over standard therapies for RRMM	3
Therapeutic targeting of mismatch repair-deficient cancers	3
Bemarituzumab enters the FIGHT	3
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection	3
Emerging importance of HER3 in tumorigenesis and cancer therapy	3
THOR provides new data on the efficacy of erdafitinib	3
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	3
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches	3
The development of CAR T cells for patients with CNS malignancies	3
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC	3